|
New collaboration with Sahlgrenska Science Park |
|
Tuesday, 07 September 2010 11:30 |
|
Bio-Medisinsk Innovasjon AS (BMI) and Sahlgrenska Science Park (SSP) have agreed to collaborate in order to advance their efforts in the commercialization of biomedical research.
BMI and SSP both operate by providing capital and management expertise to enable a fast and efficient progress of selected projects within the field of biotechnology, with the aim is to reduce risk and increase the success rates for early start-ups. As both financial and human resources are decisive in this area, a closer collaboration will greatly increase the chances of success for both organizations and their portfolio of projects and start-up companies.
“We will meet on a regular basis with the aim of increasing the scientific and commercial progress for our portfolio through exchange of information and expertise, but also to learn from each other”, says Ingrid Alfheim, CEO of BMI.
“Our collaboration will help our projects and companies gain even more”, says Gunilla Bökmark, CEO of SSP
More info:
Contact info Bio-Medisinsk Innovasjon AS (BMI): Ingrid Alfheim, CEO, ingrid[at]bmioslo.no, Tel: (+47) 22958190
Contact Sahlgrenska Science Park (SSP): Gunilla Bökmark, CEO, gunilla.bokmark[at]sahlgrenskasciencepark.se, Tel: (+46) (0)031-741 17 07 |
|
Collaboration agreement with LU Bio |
|
Tuesday, 07 September 2010 09:30 |
|
Bio-Medisinsk Innovasjon AS (BMI) and Lund University Bioscience AB (LU Bio) has decided to co-operate in order to leverage their activities in development of bioscience inventions.
BMI and LU Bio are both early stage investors active within the field of biomedicine. As both financial resources and pharmaceutical development experience are decisive, a closer collaboration will greatly increase the chances of success for both organizations and their portfolio companies.
“We will meet on a regular basis with the aim of making syndicate investments, but also to learn from the other’s experience”, says Ingrid Alfheim, the CEO of BMI. “We have excellent people in both organizations with different fields of competence and knowledge, all needed for successful commercialization of biomedical projects. The combination of skills in both teams will act in a synergistic manner”.
“In Sweden we have a history of pharmaceutical industry, and consequently industrial experience available for startup companies. We find great science in both countries, and we believe that the opportunity for international success will increase by picking the winners and jointly support them”, says Thomas Anderson, CEO of LU Bio.
At the moment BMI is actively involved in the management of 6 companies, whereof 3 (Vaccibody, Nextera and siRNAsense) are devoted to development of effective cancer therapies. Also LU Bio is involved in cancer therapy as lead investor in Cantargia AB that develops an effective therapy targeting leukemic stem cells. Today LU Bio is actively involved in the management of 5 companies.
More info:
Contact info Bio-Medisinsk Innovasjon AS (BMI): Ingrid Alfheim, CEO, ingrid[at]bmioslo.no, Tel: (+47) 22958190
Contact Lund University Bioscience (LU Bio): Thomas Andersson, CEO, thomas[at]lubio.se, Tel: (+46) (0)46 286 48 21
|
|
Serodus acquires ZP120, an ORL-1 agonist, from Zealand Pharma |
|
Monday, 06 September 2010 11:30 |
|
Serodus AS has acquired the rights to Zealand Pharma's ORL-1 agonist ZP120.
Serodus intends to develop the compound for the treatment of patients with isolated systolic hypertension. ZP120 has previously been studied in patients with chronic and acute heart failure. Under Serodus' development, ZP120 will be given the code SER100.
More info: trygve[at]serodus.com, Tlf: (+47) 22958191
|
|
Nextera AS licenses complementing technologies from Birkeland Innovasjon AS |
|
Tuesday, 17 August 2010 11:30 |
|
The Deltaphage and MHC II related technologies are potent building blocks in Nextera's platform technology.
Deltaphage is a helper phage specially designed for optimized pIX display. The MHC II related technology allows efficient presentation of MHC II on phage, opening both for drug discovery for this class of molecules with an unprecedented speed and quality.
More info:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
, Tlf: (+47) 22958192
|
|
siRNAsense-patent approved in EPO |
|
Monday, 25 January 2010 11:30 |
|
siRNAsense has been notified that patent will be granted in EPO on drug composition for its lead drug candidate, siRNA targeting Tissue Factor for treatment of cancer metastases. Patents are already approved in Japan and Australia.
More info: hannemette[at]sirnasense.com, Tlf: (+47) 22958192
|
|
Nextera AS is established |
|
Friday, 09 October 2009 06:10 |
|
In August 2009, the company Nextera AS was established, based on a proprietary new phage display technology. Nextera utilizes the pVII capsid protein of filamentous bacteriophages as a scaffold for display of peptides and proteins.
Geir Åge Løset, the inventor of the technology, will be central in developing the company forward. He has his background from the group of Professor Inger Sandlie at the Department of Molecular Biosciences, the University of Oslo, a lab with a world class track record within engineering of biological molecules such as antibodies and T-cell receptors. Professor Sandlie has over the last twenty years had a strong focus on engineering of the specific detecting molecules of the adaptive immune system, with an aim of developing new therapeutic molecules. The invention which is the basis for the company formation, brings the potential of simplifying detection and maturation of new potential biological drugs. Nextera AS has a close relationship to Bio-Medisinsk Innovasjon AS, the main owner of the company, an incubator and investor with focus on strategic business development. Birkeland Innovasjon AS, the TTO for the University of Oslo, is also a shareholder of the company. More info: ohbrekke[at]nextera.no, Tlf: (+47) 22958193 |
|
Innovation Norway supports Vaccibody |
|
Friday, 25 September 2009 09:10 |
Vaccibody has received a grant of 1.4 million NOK from Innovation Norway. The grant supports the company's preclinical program that aims for clinical phase I trial.
“We are highly satisfied to get this grant from Innovation Norway. This tells us that we are in the forefront of Norwegian biotech industry. Obtaining such a grant will definitely help us in the further capitalization needed to bring the Vaccibody technology towards a clinical proof of concept “ CEO, Ole Henrik Brekke says in a comment. Vaccibody AS is a vaccine development company based on a unique technology that enhances the human immune responses compared to other vaccines. The Vaccibody technology allows for the development of therapeutic vaccines. Vaccibody is developing vaccines targeting cancers and infectious diseases. More info: ohbrekke[at]vaccibody.com, Tlf: (+47) 22958193 |
|
Vaccibody making headlines |
|
Tuesday, 15 September 2009 12:10 |
Vaccibody was thoroughly presented in an article in the Norwegian financial newspaper "Dagens Næringsliv" on Saturday 12th September.
The article discusses new vaccine technology with focus on DNA vaccines. Vaccibody is a vaccine delivery technology that fosters beneficial effects of DNA vaccines and may be the promise for bringing such vaccines closer to the market. More info: ohbrekke[at]vaccibody.com, Tlf: (+47) 22958193 |
|
Vaccibody appoints new Chairman of the Board of Directors |
|
Wednesday, 17 June 2009 12:10 |
|
Following the recent capitalization, Vaccibody has expanded its board and appointed Tom Pike as its chairman. The Board of Directors is now constituted by Tom E. Pike, Erlend Skagseth, Mona Møller and Ingrid Alfheim. For resumes, see http://www.vaccibody.com, section “Board of Directors”. “We are delighted that Tom Pike has joined the company as our new chairman. With his experience from international pharmaceutical industry he will bring valuable knowledge and network into the company “ Ole Henrik Brekke, CEO Vaccibody AS, says in a comment. More info: ohbrekke[at]vaccibody.com, Tlf: (+47) 22958193 |
|
Sarsia Seed invests in Vaccibody AS |
|
Wednesday, 10 June 2009 12:10 |
|
Sarsia Seed AS and Vaccibody AS has signed an investment agreement fostering further company development of Vaccibody AS, the company announced April 30th. Vaccibody AS was until now fully owned by Bio-Medisinsk Innovasjon AS, and by the current agreement Sarsia Seed AS will obtain 22,5% of the company shares. “This investment allows for the continuity of our internal pipeline and external collaborations. It is especially satisfactory to obtain such investment during the current global financial situation and we are highly delighted to have Sarsia Seed on board bringing on important network for the further development of Vaccibody”, Ole Henrik Brekke, CEO Vaccibody AS, says in a comment. More info: ohbrekke[at]vaccibody.com, Tlf: (+47) 22958193 |
|
|
